31 March 2025
: Case report
[In Press] Atorvastatin-Associated Acute Pancreatitis: A Case Report
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Fahad Alshammari1BDEF, Alwaleed Alharbi1ADF, Reem Ali Alshammari2BEDOI: 10.12659/AJCR.945772
Am J Case Rep In Press; DOI: 10.12659/AJCR.945772
Available online: 2025-03-31, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Acute pancreatitis (AP) occurs when pancreatic enzymes activate within the pancreas, causing damage. In the USA, 210 000 patients are hospitalized annually due to AP. Although statin-induced pancreatitis is rare and often misdiagnosed, it is crucial to investigate, as avoiding the causative medication can prevent attacks. There is conflicting evidence, and further research is needed to determine if statins increase the risk of AP.
CASE REPORT
In this report, we detail the case of a 48-year-old man with a history of dyslipidemia, for which he was prescribed atorvastatin 40 mg/day as a lipid-lowering agent. He developed acute pancreatitis after using atorvastatin. He initially presented to the emergency room with worsening epigastric pain. Elevated levels of lipase, amylase, and alanine aminotransferases in laboratory tests indicated acute pancreatitis. Given these findings, supportive care was promptly initiated, and atorvastatin, identified as the potential trigger, was discontinued. Notably, the patient had no history of alcohol or tobacco use, and extensive diagnostic efforts ruled out other common causes of acute pancreatitis. The absence of other risk factors reinforced the likelihood that atorvastatin was responsible for his condition, as noted in Table 2. This case underscores the importance of careful monitoring of symptoms and laboratory findings in patients treated with statin medications, particularly when prescribed for dyslipidemia.
CONCLUSIONS
Documenting such unusual cases could help highlight the potential risks of acute pancreatitis associated with statin use.
Keywords: Dyslipidemias; Cardiology; Pancreatitis; Atorvastatin
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946800
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947628
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947148
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946611
Most Viewed Current Articles
21 Jun 2024 : Case report
97,828
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,727
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
32,839
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,613
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030